WZWen-Yan Zhu

Wen-Yan Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wen-Yan Zhu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Changlin Li

    Department of Oncology, Chengdu Seventh People’s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, China

    1 shared publication
  • Cheng Yi

    West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China

    1 shared publication
  • Deng Pan

    Department of Medical Oncology, Guangxi Academy of Medical Sciences and the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Hong Zhu

    Institute of Pharmacology & Toxicology, Zhejiang Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

    1 shared publication
  • Li Ma

    Department of Oncology, Chengdu Seventh People’s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, China

    1 shared publication
  • Mingfu Ding

    Rehabilitation Medicine Department, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    Distinct experiences and care needs of advanced cancer patients with good ECOG performance status: a qualitative phenomenological study

    by Ping Chen, Mingfu Ding, Changlin Li, Yujuan Long, Deng Pan, Li Ma, Taiguo Liu, Cheng Yi

    Advanced cancer patients with good Eastern Cooperative Oncology Group (ECOG) performance status (score 0–1) are underrepresented in current qualitative reports compared with their dying counterparts. To explore the experiences and care needs of advanced cancer patients with good ECOG. A qualitative phenomenological approach using semi-structured interview was employed. Data was analyzed using the Colaizzi’s method. Purposive sample of terminal solid cancer patients on palliative care aged 18–70 years with a 0–1 ECOG score were recruited from a tertiary general hospital. Sixteen participants were interviewed. Seven themes were generated from the transcripts, including experiencing no or mild symptoms; independence in self-care, decision-making, and financial capacity; prioritization of cancer growth suppression over symptom management; financial concerns; hope for prognosis and life; reluctance to discuss death and after-death arrangements; and use of complementary and alternative medicine (CAM) and religious coping. Advanced cancer patients with good ECOG have distinct experiences and care needs from their dying counterparts. They tend to experience no or mild symptoms, demonstrate a strong sense of independence, and prioritize cancer suppression over symptom management. Financial concerns were common and impact their care-related decision-making. Though being hopeful for their prognosis and life, many are reluctant to discuss death and after-death arrangements. Many Chinese patients use herbal medicine as a CAM modality but need improved awareness of and accessibility to treatment options. Healthcare professionals and policy-makers should recognize their unique experiences and needs when tailoring care strategies and policies. What is already known about the topic? • Even in their advanced stage, cancer patients with good ECOG performance status are capable of self-care and less reliant on care provided by other. • Existing qualitative research mainly focuses on advanced cancer patients with poor ECOG, emphasizing pain management, emotional distress, and palliative care. What this paper adds? • Our findings reveal distinct experiences and care needs of advanced cancer patients with good ECOG performance status from their dying counterparts. Implications for practice, theory or policy. • Healthcare professionals should recognize and address the patient group’s distinct needs. • Future research should further investigate their symptom trajectory, influencing factors, and care needs to fill the gap in their cancer journey. • Policy-makers should develop tailored policies that consider good ECOG performance status.


  • Long-term recurrence-free survival in a patient with pancreatic carcinosarcoma: A case report with a literature review

    by Wen-Yan Zhu, Tai-Guo Liu, Hong Zhu

    Here, we presented a case of carcinosarcoma of the pancreas in a 53-year-old woman. The carcinosarcoma was in the head of pancreas. She underwent a pancreaticoduodenectomy. The tumor was grossly yellowish-whitish. Histologic evaluation of the tumor revealed 2 elements separated from each other. One component was conventional pancreatic ductal adenocarcinoma, and the other component showed sarcomatous growth pattern composed of pleomorphic spindle cells. Immunohistochemically, the adenocarcinoma component was reactive for antibodies to cytokeratin 18 and epithelial membrane antigen. The sarcomatous component was reactive for smooth muscle antibody. These findings led to a diagnosis of pancreatic carcinosarcoma. The patient was treated with gemcitabine, adriamycin, and cisplatin after the operation. Although previously reported patients with pancreatic carcinosarcoma showed a very poor outcome, this patient has remained free of recurrence for 20 months, which is the longest recurrence-free survival time recorded for this type of cancer. This treatment plan may be a feasible option.